Of note, based on recent molecular subtypes, EBV-positive and MSI-H GCs emerge as the best candidates for immunotherapy based on the increased PD-L1 expression associated with these subtypes and the high tumor mutational load in MSI-H GEA, which has been shown to correlate with a greater benefit from anti-PD-1/PD-L1 blockade [87]. The gene discussed is CD274; the disease is neoplasm.